

Review

Trends in drug discrimination research analysed with a cross-indexed bibliography, 1982-1983

I.P. Stolerman and P.J. Shine

Departments of Pharmacology and Psychiatry, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK

The drug discrimination procedure has become one of the most widely used paradigms in behavioural pharmacology, a situation which is reflected in the appearance to date of more 600 publications, including the proceedings of a number of symposia. Advances in technique have made drug discrimination techniques among the most powerful available to behavioural pharmacologists, and a very large amount of information on a wide range of drugs from different pharmacological classes has been obtained under strictly comparable experimental conditions. Stolerman et al. (1982, in reference 34) compiled a bibliography of drug discrimination research for 1950-1981. This has now been extended to include the years 1982-1983. Analysis of the bibliographic information facilitates quantification of recent research activity in the field and makes apparent certain trends and omissions that might otherwise be difficult to perceive.

There follows a brief discussion of some of these trends, relating mainly to the types of drugs studied and the relative use or neglect of specific experimental procedures. The current bibliographic listing of 191 articles is then given, together with an index enabling papers dealing with specific aspects of the subject to be identified readily.

Growth of the Field

The development of the field may be gauged from Fig. 1, which shows the numbers of papers published during each of the last 33 years. After a period of relative inactivity, rapid growth began in 1971. The most recent data provide no clear indication that this stage has yet been passed: the present bibliography contains 82 and 61 entries for 1982 and 1983 respectively (excluding the individual papers in the drug discrimination symposium). The largest number of entries recorded previously was 64, in 1981. A small number of earlier articles is also included in the present listing, so that when it is used in conjunction with the earlier version, almost complete coverage is provided for the years 1951-1983.

It may be noted that during the 1960's, most research papers were concerned with demonstrating the basic phenomenon under study and with defining some of its fundamental characteristics. During the early 1970's different methods were evaluated and some degree of standardiza-




Fig. 1. Growth of the literature on drug discrimination research over 32 years since the first report appeared. Abstracts, research papers, reviews, and books were included to produce this diagram. Individual papers in several books devoted primarily to drug discrimination research were excluded because they distort the trends shown in the figure

tion developed. In the mid-1970's drug discrimination began to be widely applied in diverse areas where, most commonly, it provided a specific and quantitative behavioural assay in studies of the neuropharmacological mode of action of drugs. Now we are at a stage where discriminative effects of drugs are often used alongside classical techniques without serving as the primary focus of study. Indeed, authors do not always indicate the use of drug-discrimination methodology in the titles of their papers, making it increasingly difficult for such work to be identified. There is a trend apparent for the full potential of drug discrimination techniques to be obscured by the emphasis on the neuropharmacological application. Virtually no work has been reported on the possible discriminative effects of naturally-occurring substances (e.g., neurotransmitters and hormones) at physiological concentrations, and the significance of the purported relationship of discriminative drug effects with subjective effects remains in doubt.

Pharmacological aspects

The indexing of articles according to drugs used for training discriminations makes it easy to quantify research activity directed to different pharmacological classes. In the period 1982-1983, the largest numbers of investigations involved

training subjects to discriminate sedative-hypnotic drugs including alcohol [57]. The figures in square brackets indicate total numbers of citations on a topic. Within this class, there were 24 studies of benzodiazepine discrimination, 22 of barbiturates and 13 of ethanol. Diazepam and pentobarbitone seem to have been regarded as prototypical agents and have been used as training stimuli more frequently than other compounds: the reasoning behind this remains obscure and, with certain exceptions, these studies seem rather far removed from present knowledge of the drugs' mode of action at the neurochemical level.

Opioid drugs formed the basis of 48 studies. The most popular agents for training have been morphine [15] and fentanyl [11], compounds generally regarded as agonists at the mu-subtype of opioid receptors. Relatively few studies have used kappa-agonists such as ethylketocyclazocine [7] or sigma-agonists such as SKF 10,047 [5], or have used compounds selected primarily for their opioid-antagonist effects [8]. Nevertheless, despite the overwhelming popularity of the putative mu-agonists, drug discrimination techniques have provided some of the best behavioural evidence for the existence of opioid receptor subtypes and generally, this is an area where the neurochemical and behavioural work seems to have been particularly well co-ordinated. Opioid peptides have received less attention than might be expected: no such compound seems to have been used to establish a discrimination and in only a few studies have they been used in generalization tests.

Drug discrimination techniques also appear to have been much favoured by researchers interested in hallucinogenic agents [50]. The greatest emphasis seems to have been placed on the dissociative anaesthetics, phencyclidine, and ketamine [30], followed by the LSD- and DOM-like compounds [27]. Particularly strong correlations of discriminative effects with certain neurochemical actions have been reported for the LSD-DOM class. This level of research activity is interesting when considered in relation to the lack of therapeutic value of hallucinogenic agents.

The only other class of drug which has been the subject of fairly widespread research has been the psychomotor stimulants [22], including studies with (+)-amphetamine [17] and cocaine [9]. The use of these compounds seems to have declined, perhaps because they were studied so intensively in earlier years and because their mode of action seemed so well understood. Interest in nicotine seems to have been maintained [11] and may grow as the importance of central nicotinic mechanisms is increasingly recognized. Agents from the wide spectrum of analeptic (convulsant) drugs were used as training stimuli in only 10 studies. Some of these compounds have anxiogenic effects, and the potential value of their discriminative stimulus properties for providing animal analogues of anxiety suggests that this area may develop rapidly. Antidepressants, neuroleptics, and muscarinic-cholinergic antagonists have been almost completely ignored as training stimuli in recent years, generating only two studies each.

Antidepressants and neuroleptics have proved more difficult than most types of drug to study with existing discriminative techniques. The low level of interest in the anticholinergics is more surprising, especially in view of the important role they played in drug discrimination studies in the early years of the field and the current interest in cholinergic mechanisms in memory and Alzheimer's disease. Cannabis derivatives also seem unfashionable [2]!

Methodological aspects

Although drug discrimination techniques have a lot in common with each other, the relative merits of different approaches have been much debated over the years. The use of maze-running techniques has declined [7]. Almost all other studies used an operant conditioning paradigm involving response choice, such as the two-bar procedure or a development of it such as a three-choice technique. Rats were the subjects most widely used [128], followed by birds [26] and monkeys [23]. Of mice and men there were two studies each.

There were large variations in the schedules maintaining the baselines of behaviour upon which drug discriminations were developed. Food was the preferred reinforcing event [126], followed by shock escape-avoidance [25], water [11], electrical stimulation of the brain [3] and money [1]. Fixed ratio schedules predominated [103] followed by variable intervals [24]. Continuous reinforcement was used mainly in connection with shock escape-avoidance, whereas small bands of enthusiasts continued to show their preference for tandem variable interval fixed ratio schedules [9], fixed interval schedules [1] and interlocking schedules [1]. One innovation has been the introduction of second order schedules together with a colour-tracking procedure [4]. More work has been done with fixed ratio schedules of food presentation [87] than with any other schedule, and most of these studies used rats [51].

There have also been examinations of the time-courses of drug action [24], the role of training dose [18], drug versus drug discriminations [13] and chronic effects such as tolerance and dependence [10]. Fewer studies have looked at discriminations between different doses of the same drug [5] or at interactions of drug-produced stimuli with exteroceptive cues [5].

Using the bibliographic index

The list of references is followed by an index which refers back to the numbers of articles in the list. The index is primarily pharmacological, although species, and procedural variables are also included. Each drug in the index is followed by a list of articles where its use as a training drug was reported. Additional entries in the index show when the drug was used in cross-tests (generalization tests), or as a pretreatment in attempts to modify discriminative drug effects. This feature makes it very easy to obtain comprehensive lists of studies where a selected drug or class of drugs has been used in a particular way, and it has been found very useful when planning research or preparing manuscripts. It is possible to carry out a limited number of more specific searches using combinations of two or more keywords, or to supply the data base itself to people with access to suitable computing facilities. Readers interested in either of these possibilities, or who might like to obtain a combined listing for 1951-1983, with index, should contact the senior author.

The bibliography and index was prepared with the aid of the FAMULUS library of programmes running at the University of London Computer Centre. We thank Mr. R.E. Baldy for guidance in the use of FAMULUS.

References

- Altshuler HL, Shippenberg TS (1982) Tetrahydroisoquinoline and opioid substrates of alcohol actions. *Prog Clin Biol Res*. Beta-Carbolines and tetrahydroisoquinolines. Bloom F, Barchas J, Sandler M, Usdin E (eds) Alan R Liss, New York 90:329-344
- Appel JB, White FJ, Holohean AM (1982) Analysing mechanism(s) of hallucinogenic drug action with drug discrimination procedures. *Neurosci Biobehav Rev* 6:529-536
- Appel JR, White FJ, West KB, Holohean AM (1982) Discriminative stimulus properties of ergot alkaloids. Drug discrimination: Applications in CNS pharmacology. Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 49-67
- Ator NA, Griffiths RR (1982) Drug discrimination and generalization in lorazepam- and pentobarbital-trained baboons: interactions with a benzodiazepine antagonist *Fedn Proc* 41:1071
- Ator NA, Griffiths RR (1983) Lorazepam and pentobarbital drug discrimination in baboons: Cross-drug generalization and interaction with Ro 15-1788. *J Pharmac Exp Ther* 226:776-782
- Balster RL, Brady KT (1982) Similarities in the discriminative stimulus properties of (+)-N-allylnormetazocine and phencyclidine in rats. Drug discrimination: Applications in CNS Pharmacology. Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 99-108
- Barrett RJ, Blackshear MA, Sanders-Bush E (1982) Discriminative stimulus properties of L-5-Hydroxytryptophan: behavioral evidence for multiple serotonin receptors. *Psychopharmacology* 76:29-35
- Barrett RJ, Steranka LR (1983) Drug discrimination in rats: evidence for amphetamine-like cue state following chronic haloperidol. *Pharmac Biochem Behav* 18:611-617
- Barry H III, McGuire MS, Krimmer EC (1982) Alcohol and meprobamate resemble pentobarbital rather than chlordiazepoxide. Drug discrimination: Applications in CNS Pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 219-233
- Bennett DA, Geyer H, Dutta P, Brugger S, Fielding S, Lal H (1982) Comparison of the actions of trimethadione and chlordiazepoxide in animal models of anxiety and benzodiazepine receptor binding. *Neuropharmacology* 21:1175-1179
- Bennett DA, Lal H (1982) Discriminative stimuli produced by clonidine: An investigation of the possible relationship to adrenoceptor stimulation and hypotension. *J Pharmac Exp Ther* 223:642-648
- Bennett DA, Lal H (1982) Discriminative stimuli produced by clonidine: possible relationship to central noradrenergic hypoactivity and hypotension. *Fedn Proc* 41:1536
- Bennett DA, Lal H (1982) Discriminative stimulus properties of the vasodilator, hydralazine; differential generalization with alpha-one and alpha-two adrenoceptor drugs. *Prog Neuro-Psychopharmacol Biol Psychiat* 6:17-26
- Bertalmio AJ, Herling S, Hampton RY, Winger G, Woods JH (1982) A procedure for rapid evaluation of the discriminative stimulus effects of drugs. *J Pharmacol Methods* 7:289-299
- Brady KT, Balster RL (1982) Discriminative stimulus properties of ketamine stereoisomers in phencyclidine-trained rats. *Pharmac Biochem Behav* 17:291-295
- Brady KT, Balster RL (1982) Discriminative stimulus properties of stereoisomers of cyclazocine in phencyclidine-trained squirrel monkeys. *Life Sci* 31:541-549
- Brady KT, Balster RL, May EL (1982) Stereoisomers of N-allylnormetazocine: phencyclidine-like behavioral effects in squirrel monkeys and rats. *Science* 215:178-180
- Brady KT, Woolverton WL, Balster RL (1982) Discriminative stimulus and reinforcing properties of etoxadrol and dexoadrol in monkeys. *J Pharmac Exp Ther* 220:56-62
- Browne, RG (1982) Discriminative stimulus properties of phencyclidine. Drug discrimination: Applications in CNS pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 109-122
- Browne RG, Koe BK (1982) Clozapine and agents with similar behavioral and biochemical properties. Drug discrimination: Applications in CNS Pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 241-254
- Browne RG, Weissman A (1981) Discriminative stimulus properties of delta-9-tetrahydrocannabinol: Mechanistic studies. *J Clin Pharmac* 21:227-234S
- Browne RG, Welch WM (1982) Stereoselective antagonism of phencyclidine's discriminative properties by adenosine receptor agonists. *Science* 217:1157-1159
- Bueno OFA, Carlini EA (1972) Dissociation of learning in marijuana tolerant rats. *Psychopharmacologia* 25:49-56
- Carter RB, Leander JD (1982) Discriminative stimulus properties of naloxone. *Psychopharmacology* 77:305-308
- Cervo L, Woolverton WL (1983) The effects of desmethyldipratinine (DMI) + 6-Hydroxydopamine (6-OHDA) on the discriminative stimulus properties of d-amphetamine and apomorphine in rats. *Fed Proc* 42:621
- Chipkin RE, Melchior CL, Deitrich RA (1979) Interaction of carboxysalsolinol with the ethanol discriminative stimulus. *Commun Psychopharmacol* 3:159-164
- Colpaert FC (1982) Increased naloxone reversibility in fentanyl dose-dose discrimination. *Eur J Pharmac* 84:229-231
- Colpaert FC (1982) The pharmacological specificity of opiate drug discrimination. Drug discrimination: Applications in CNS pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 3-16
- Colpaert FC, Janssen PAJ (1982) Factors regulating drug cue sensitivity: limits of discriminability and the role of a progressively decreasing training dose in cocaine-saline discrimination. *Neuropharmacology* 21:1187-1194
- Colpaert FC, Janssen PAJ (1982) Factors regulating drug cue sensitivity: the effects of dose ratio and absolute dose level in the case of fentanyl dose-dose discrimination. *Arch Int Pharmacodyn Ther* 258:283-299
- Colpaert FC, Janssen PAJ (1982) OR discrimination: A new drug discrimination method. *Eur J Pharmac* 78:141-144
- Colpaert FC, Janssen PAJ (1983) A characterization of LSD-antagonist effects of pirenperone in the rat. *Neuropharmacology* 22:1001-1005
- Colpaert FC, Niemegeers CJE, Janssen PAJ (1982) A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-Antagonist. *J Pharmac Exp Ther* 221:206-214
- Colpaert FC, Slangen JL (1982) Drug discrimination: Applications in CNS pharmacology. Elsevier, Amsterdam
- Connelly JF, Connelly JM, Epps JO (1973) Disruption of dissociated learning in a discrimination paradigm by emotionally important stimuli. *Psychopharmacologia* 30:275-282
- Cunningham, KA, Appel JB (1982) Discriminative stimulus properties of cocaine and phencyclidine: similarities in the mechanism of action. Drug discrimination: applications in CNS pharmacology. In: Colpaert FC, Slangen JL (ed) Elsevier, Amsterdam, pp 181-192
- D'Mello GD (1982) Comparison of the discriminative stimulus properties of clonidine and amphetamine in rats. *Neuropharmacology* 21:763-769
- Dantzer R, Perio A (1982) Behavioural evidence for partial agonist properties of Ro 15-1788, a benzodiazepine receptor antagonist. *Eur J Pharmac* 81:655-658
- De Witte Ph (1982) Brain stimulation as the reinforcer in alcohol-saline discrimination. *Pharmac Biochem Behav* 17:1093-1096
- De Witte Ph (1982) Hypothalamic brain stimulation as reward in an alcohol vs saline discrimination paradigm. Drug discrimination: applications in CNS pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 355-359
- De Witte Ph (1982) Response latency as the dependent vari-

- able in discrimination procedures. Drug discrimination: Applications in CNS Pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 361-365
42. Emmett-Oglesby MW, Spencer DG, Elmesallamy F, Lal H (1983) The pentylenetetrazol model of anxiety detects withdrawal from diazepam in rats. *Life Sci* 33:161-168
43. Emmett-Oglesby MW, Spencer DG, Lewis MW, Elmesallamy F, Lal H (1983) Anxiogenic aspects of diazepam withdrawal can be detected in animals. *Eur J Pharmacol* 92:127-130
44. Emmett-Oglesby MW, Wurst M, Lal H (1983) Discriminative stimulus properties of a small dose of cocaine. *Neuropharmacology* 22:97-102
45. Friedman R, Barrett RJ, Sanders-Bush E (1983) Additional evidence that L-5-Hydroxytryptophan discrimination models a unique serotonin receptor. *Psychopharmacology* 80:209-213
46. Garcha HS, Giardini V, Pratt JA, Stolerman IP (1983) Investigation of the effects of ganglion-blocking drugs and methergoline on the nicotine cue in rats. *Br J Pharmacol* 78:9P
47. Garcha HS, Kumar R, Pratt JA, Stolerman IP (1982) Characteristics of the nicotine cue in rats. *Br J Pharmacol* 76:227P
48. Garza RDL, Johanson CE (1983) The discriminative stimulus properties of cocaine in the rhesus monkey. *Pharmac Biochem Behav* 19:145-148
49. Garza RDL, Johanson CE, Schuster CR (1983) Discriminative stimulus effects of oxazepam and pentobarbital. *Fed Proc* 42:620
50. Genovese RF, Dykstra LA (1983) Comparison of morphine and clonidine in rats trained to discriminate morphine or clonidine from vehicle or morphine. *Fed Proc* 42:1363
51. Glennon RA, Jacyno JM, Young R (1983) A comparison of the behavioral properties of (+)-, (-)-, and ($\pm$)-5-methoxy-alpha-methyltryptamine. *Biol Psychiat* 18:493-498
52. Glennon RA, Rosecrans JA (1981) Speculations on the mechanism of action of hallucinogenic indolealkylamines. *Neurosci Biobehav Rev* 5:197-207
53. Glennon RA, Rosecrans JA, Young R (1981) Behavioral properties of psychoactive phenylisopropylamines in rats. *Eur J Pharmacol* 76:353-360
54. Glennon RA, Rosecrans JA, Young R (1982) The use of the drug discrimination paradigm for studying hallucinogenic agents. A review. Drug discrimination: applications in CNS pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 69-96
55. Glennon RA, Rosecrans JA, Young R (1983) Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents. *Med Res Rev* 3:289-340
56. Glennon RA, Schubert E, Jacyno JM (1980) Studies on several 7-substituted N,N-dimethyltryptamines. *J Med Chem* 23:1222-1226
57. Glennon RA, Young R (1982) Comparison of the behavioral properties of di- and tri-methoxyphenylisopropylamines. *Pharmac Biochem Behav* 17:603-607
58. Glennon RA, Young R, Benington F, Morin RD (1982) Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane. *J Med Chem* 25:1163-1168
59. Glennon RA, Young R, Benington F, Morin RD (1982) Hallucinogens as discriminative stimuli: a comparison of 4-OMe DMT and 5-OMe DMT with their methylthio counterparts. *Life Sci* 30:465-467
60. Glennon RA, Young R, Jacyno JM (1983) Indolealkylamine and phenalkylamine hallucinogens: effects of alpha-methyl and N-methyl substituents on behavioral activity. *Biochem Pharmacol* 32:1267-1273
61. Glennon RA, Young R, Jacyno JM, Slusher M, Rosecrans JA (1983) DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines. *Eur J Pharmacol* 86:453-459
62. Glennon RA, Young R, Rosecrans JA (1982) A comparison of the behavioral effects of DOM homologs. *Pharmac Biochem Behav* 16:557-559
63. Glennon RA, Young R, Rosecrans JA (1982) Discriminative stimulus properties of DOM and several molecular modifications. *Pharmac Biochem Behav* 16:553-556
64. Glennon RA, Young R, Rosecrans JA, Anderson GM (1982) Discriminative stimulus properties of MDA analogs. *Biol Psychiat* 17:807-814
65. Goudie AJ (1982) Discriminative stimulus properties in an operant task of beta-phenylethylamine. Drug discrimination: applications in CNS Pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 165-180
66. Griffiths RR, Ator NA, Lukas SE, Brady JV (1982) Experimental abuse liability assessment of benzodiazepines. Pharmacology of Benzodiazepines. In: Usdin E, Skolnick P, Tallman JF, Greenblatt D, Paul SM (eds) McMillan, London, pp 609-618
67. Grippo JF, Herling S, Solomon RE (1981) Ketamine-like discriminative stimulus effects of stereoisomeric pairs of opioids in pigeons. *Pharmacologist* 23:152
68. Grippo JF, Herling S, Solomon RE, Woods JH (1981) Ketamine-like discriminative stimulus effects of stereoisomeric pairs of opioids in pigeons. *Pharmacologist* 23:152
69. Grippo JF, Solomon RE, Herling S (1981) Relationship between the discriminative stimulus effects of some opioids and ketamine in pigeons. *Fed Proc* 40:246
70. Haenlein M, Caul WF, Barrett RJ, Michaelis RC (1983) Discrimination of serotonergic drugs is unaltered in rats prenatally exposed to ethanol. *Neurobehav Toxicol Teratol* 5:475-478
71. Haug T, Gotestam KG (1982) The diazepam stimulus complex. Specificity in a rat model. *Eur J Pharmacol* 80:225-230
72. Haug T, Gotestam KG (1982) Onset and offset of the diazepam stimulus complex. *Pharmac Biochem Behav* 17:1171-1174
73. Hendry JS, Balster RL, Rosecrans JA (1983) Discriminative stimulus properties of buspirone compared to central nervous system depressants in rats. *Pharmac Biochem Behav* 19:97-101
74. Herling S (1983) Naltrexone blocks the response-latency increasing effects but not the discriminative effects of diazepam in rats. *Eur J Pharmacol* 88:121-124
75. Herling S, Hein DW, Nemeth MA, Valentino RJ, Woods JH (1982) Discriminative stimulus, antagonist, and rate-decreasing effects of cyclorphan: multiple modes of action. *Life Sci* 30:331-341
76. Herling S, Sarvela PD, Coale EH (1981) Discriminative stimulus effects of dextrorphan (DXT) in pigeons. *Fed Proc* 40:246
77. Herling S, Shannon HE (1982) Discriminative effects of ethylketazocine in the rat: stereospecificity and antagonism by haloxone. *Life Sci* 31:2371-2374
78. Herling S, Shannon HE (1982) Discriminative stimulus effects of benzodiazepines (BZ) in the rat. *Fed Proc* 41:1637
79. Herling S, Shannon HE (1982) Ro 15-1788 antagonizes the discriminative stimulus effects of diazepam in rats but not similar effects of pentobarbital. *Life Sci* 31:2105-2112
80. Herling S, Solomon RE, Woods JH (1981) Ketamine-like discriminative effects of some opioids in rhesus monkeys. *Pharmacologist* 23:152
81. Herling S, Solomon RE, Woods JH (1983) Discriminative stimulus effects of dextrorphan in pigeons. *J Pharmacol Exp Ther* 227:723-731
82. Herling S, Winger G (1983) Stereospecificity in the discriminative effects of barbiturates in pigeons. *Fed Proc* 42:621
83. Hernandez LL, Holohean AM, Appel JB (1982) Morphine may mimic the apomorphine cue by inhibiting dopaminergic autoinhibition. *Eur J Pharmacol* 78:287-294
84. Holohean AM, White EJ, Appel JB (1982) Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids. *Eur J Pharmacol* 81:595-602
85. Holtzman SG (1982) Discriminative stimulus properties of opioids in the rat and squirrel monkey. Drug discrimination:

- applications in CNS pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 17-36
86. Holtzman SG (1982) Phencyclidine-like discriminative stimulus properties of opioids in the squirrel monkey. *Psychopharmacology* 77:295-304
 87. Holtzman SG (1982) Stimulus properties of opioids with mixed agonist and antagonist activity. *Fed Proc* 41:2328-2332
 88. Huang D, Wilson MC (1983) Comparative behavioral profile of DL-cathinone, D-amphetamine and cocaine in rats. *Fed Proc* 42:1159
 89. Jarbe TUC (1982) Discriminative stimulus properties of D-amphetamine in pigeons. *Pharmac Biochem Behav* 17:671-675
 90. Jarbe TUC, Hiltunen AJ, Swedberg MDB (1982) Ethanol as a discriminative stimulus: Effects of cyanamide, acetaldehyde and chlormethiazole. *Med Biol* 60:298-306
 91. Jarbe TUC, Kroon-Jarbe ER (1983) Discriminability and procedure: effects of cocaine and amphetamine. *Psychol Rep* 52:611-616
 92. Jarbe TUC, Laaksonen T, Svensson R (1983) Influence of exteroceptive contextual conditions upon internal drug stimulus control. *Psychopharmacology* 80:31-34
 93. Jarbe TUC, McMillan DE (1983) Interaction of the discriminative stimulus properties of diazepam and ethanol in pigeons. *Pharmac Biochem Behav* 18:73-80
 94. Jarbe TUC, Svensson R, Laaksonen T (1983) Conditioning of a discriminative drug stimulus: overshadowing and blocking like procedures. *Scand J Psychol* 24:325-330
 95. Jarbe TUC, Swedberg MDB (1981) Differences in the stimulus effects of CNS depressant substances as evidenced by drug vs drug discrimination techniques. *Acta Pharmacologica Toxicologia* 49 Suppl IV Abstract 45
 96. Jarbe TUC, Swedberg MDB (1982) A conceptualization of drug discrimination learning. Drug discrimination: Applications in CNS pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 327-341
 97. Jarbe TUC, Swedberg MDB (1982) Discriminative stimulus properties of drugs: a brief history and a selective review. *Scand J Psychol Suppl* 1:72-78
 98. Jasinski DR, Shannon HE, Cone EJ, Vaupel DB, Risner ME, McQuinn RL, Su T-P, Pickworth WB (1982) Interdisciplinary studies on phencyclidine. PCP (Phencyclidine): Historical and current perspectives. In: Domino EF (ed) NPP Books, Ann Arbor, pp 331-400
 99. Kallman WM, Kallman MJ, Harry GJ, Woodson PP, Rosecrans JA (1982) Nicotine as a discriminative stimulus in human subjects. Drug discrimination: Applications in CNS Pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 211-218
 100. Katz, JL, Woods JH, Winger GD, Jacobson AE (1982) Compounds of novel structure having kappa-agonist behavioral effects in rhesus monkeys. *Life Sci* 31:2375-2378
 101. Katzman NJ, Herling S, Shannon HE (1983) Discriminative properties of pentobarbital (PB): Comparisons with benzodiazepines (BZ) and other sedative-hypnotics in rats. *Fed Proc* 42:344
 102. Koek W, Slangen JL (1982) Effects of reinforcement differences between drug and saline sessions on discriminative stimulus properties of fentanyl. Drug discrimination: applications in CNS Pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 343-354
 103. Koek W, Slangen JL (1982) The role of fentanyl training dose and of the alternative stimulus condition in drug generalization. *Psychopharmacology* 76:149-156
 104. Koerner J, Appel JB (1982) Psilocybin as a discriminative stimulus: lack of specificity in an animal behavior model for hallucinogens psychopharmacology 76:130-135
 105. Krafft K, Cleary J, Poling A (1983) Discriminative stimulus properties of phenytoin in the pigeon. *Psychopharmacology* 79:82-83
 106. Krimmer EC, Barry H III (1982) Measuring antagonism of discriminative opioid stimulus. *Fed Proc* 41:2319-2322
 107. Krimmer EC, Barry H III, Alvin JD (1982) Discriminative, disinhibitory, and depressant effects of several anticonvulsants. *Psychopharmacology* 78:28-32
 108. Krimmer EC, Benson BJ, McQuire MS, Barry H III (1982) Conditional sensory stimuli during morphine discrimination. Drug discrimination: Applications in CNS pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 135-145
 109. Krynock GM, Rosecrans JA (1979) Morphine as a discriminative stimulus: Role of periaqueductal grey neurons. *Res Comm Chem Pathol Pharmacol* 23:49-60
 110. Lal H, Emmett-Oglesby MW (1983) Behavioral analogues of anxiety: animal models. *Neuropharmacology* 22:1423-1441
 111. Lal H, Emmett-Oglesby MW, Spencer DG, Elmesallamy F (1983) Evidence for behavioral signs analogous to anxiety caused by withdrawal from diazepam in the rat. *Fed Proc* 42:1166
 112. Leander, JD (1982) Opioid agonist and antagonist behavioral effects of buprenorphine. *Fed Proc* 41:1317
 113. McElroy JF, Feldman RS (1982) Generalization between benzodiazepine- and triazolopyridazine discriminative cues. *Pharmac Biochem Behav* 17:709-713
 114. McMillan DE (1982) Generalization of the discriminative stimulus properties of phencyclidine to other drugs in the pigeon using color tracking under second order schedules. *Psychopharmacology* 78:131-134
 115. McMillan DE, Cole-Fullenwider DA, Hardwick WC, Wenger GR (1981) Phencyclidine discrimination in the pigeon using a color tracking procedure. *Fed Proc* 40:317
 116. McMillan DE, Cole-Fullenwider DA, Hardwick WC, Wenger GR (1982) Phencyclidine discrimination in the pigeon using color tracking under second-order schedules. *J Exp Anal Behav* 37:143-147
 117. McMillan DE, Wenger GR (1983) Schedule-induced bias of phencyclidine (PCP) discrimination in the pigeon. *Fed Proc* 42:1167
 118. Minnema D, Krynock G, Young R, Glennon RA, Rosecrans JA (1980) LSD as a discriminative stimulus: role of dorsal raphe nucleus. Substance and alcohol actions/misuse 1:29-34
 119. Mueller CW, Lisman SA, Spear NE (1982) A human memory investigation of drug discriminations and state dissociations with alcohol. Drug discrimination: Applications in CNS pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 269-285
 120. Nielsen EB, Valentine JD, Holohean AM, Appel JB (1983) Benzodiazepine receptor mediated discriminative cues: effect of GABA-ergic drugs and inverse agonists. *Life Sci* 33:2213-2220
 121. Overton DA (1982) Memory retrieval failures produced by changes in drug state. Expression of knowledge. In: Isaacson RL, Spear NE (eds) Plenum, New York, pp 113-139
 122. Overton DA (1982) Comparison of the degree of discriminability of various drugs using the T-maze drug discrimination paradigm. *Psychopharmacology* 76:385-395
 123. Overton DA (1982) Multiple drug training as a method for increasing the specificity of the drug discrimination procedure. *J Pharmac Exp Ther* 221:166-172
 124. Overton DA (1983) Test for a neurochemically specific mechanism mediating drug discriminations and for stimulus masking. *Psychopharmacology* 81:340-344
 125. Paule MG, Wenger GR (1983) Morphine discrimination in the pigeon using the color tracking procedure. *Fed Proc* 42:770
 126. Porsolt RD, Pawelec C, Jalfre M (1982) Use of a drug discrimination procedure to detect amphetamine-like effects of antidepressants. Drug discrimination: applications in CNS Pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 193-202
 127. Pratt JA, Stoleran IP, Garcha HS, Giardini V, Feyerabend

- C (1983) Discriminative stimulus properties of nicotine: further evidence for mediation at a cholinergic receptor. *Psychopharmacology* 81: 54-60
128. Priestley T (1983) Buprenorphine: stimulus generalisation to morphine - evidence for an action at the opiate mu-receptor. *Br J Pharmac* 79: 276 p
129. Revusky S, Coombes S, Pohl RW (1982) Drug states as discriminative stimuli in a flavor-aversion learning experiment. *J Comp Physiol Psychol* 96: 200-211
130. Rosecrans JA, Meltzer LT (1981) Central sites and mechanisms of action of nicotine. *Neurosci Biobehav Rev* 5: 497-501
131. Schechter MD (1983) Discriminative stimulus control with imipramine: transfer to other antidepressants. *Pharmac Biochem Behav* 19: 751-754
132. Schechter MD (1983) Behavioral interactions of coadministered amphetamine and pentobarbital. *Eur J Pharmac* 86: 447-451
133. Schechter MD (1983) Drug sensitivity of individual rats determines degree of drug discrimination. *Pharmac Biochem Behav* 19: 1-4
134. Schechter MD, Concannon JT (1982) Dopaminergic activities of quipazine. *Pharmac Biochem Behav* 17: 393-397
135. Schechter MD, Concannon JT, Maloney RE, Bellush L (1983) Can ACTH analogs support discriminative learning in rats. *Peptides (Fayetteville)* 4: 11-14
136. Schechter MD, Greer NL (1983) Phenytoin: Similarity to tricyclic antidepressants. *Pharmac Biochem Behav* 19: 415-417
137. Schuster CR, Fischman MW, Johanson CE (1981) Internal stimulus control and the subjective effects of drugs. NIDA monograph 37. Behavioral pharmacology of human drug dependence. US Government Printing Office, Washington DC, pp 116-129
138. Shannon HE (1982) Pharmacological analysis of the phencyclidine-like discriminative stimulus properties of narcotic derivatives in rats. *J Pharmac Exp Ther* 222: 146-151
139. Shannon HE (1982) Phencyclidine-like discriminative stimuli of (+) and (-)-N-allylnormetazocine in rats. *Eur J Pharmac* 84: 225-228
140. Shannon HE (1983) CGS 8216 (2-phenylpyrazolo(4,3-C)quinolin-3(5H)-one) antagonizes the discriminative stimulus properties of diazepam in an uncompetitive manner. *Fed Proc* 42: 344
141. Shannon HE (1983) Pharmacological evaluation of N-allylnormetazocine (SKF 10,047) on the basis of its discriminative stimulus properties in the rat. *J Pharmac Exp Ther* 225: 144-152
142. Shannon HE, Herling S (1983) Antagonism of the discriminative effects of diazepam by pyrazoloquinolines in rats. *Eur J Pharmac* 92: 155-157
143. Shannon HE, Herling S (1983) Discriminative stimulus effects of diazepam in rats: evidence for a maximal effect. *J Pharmac Exp Ther* 227: 160-166
144. Shannon HE, McQuinn RI, Vaupel B, Cone EJ (1983) Effects of cycloalkyl analogs of phencyclidine on behavior in rodents. *J Pharmac Exp Ther* 224: 327-333
145. Shannon HE, Su T-P (1982) Effects of the combination of tripeleminamine and pentazocine at the behavioral and molecular levels. *Pharmac Biochem Behav* 17: 789-795
146. Shearman GT, Herz A (1982) D-Ala-2, D-Leu-5-Enkephalin generalizes to a discriminative stimulus produced by fentanyl but not ethylketocyclazocine. *Pharmac Biochem Behav* 16: 249-252
147. Shearman GT, Herz A (1982) Discriminative stimulus properties of narcotic and non-narcotic drugs in rats trained to discriminate opiate κ -receptor agonists. *Psychopharmacology* 78: 63-66
148. Shearman GT, Herz A (1982) Evidence that the discriminative stimulus properties of fentanyl and ethylketocyclazocine are mediated by an interaction with different opiate receptors. *J Pharmac Exp Ther* 221: 735-738
149. Shearman GT, Herz A (1982) Generalization and antagonism studies with rats trained to discriminate an effect of the proposed sigma opiate receptor agonist N-allylnormetazocine (SKF 10,047). Drug discrimination: Applications in CNS Pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 37-47
150. Shearman GT, Herz A (1982) Non-opioid psychotomimetic-like discriminative stimulus properties of N-allylnormetazocine (SKF 10,047) in the rat. *Eur J Pharmac* 82: 167-172
151. Shearman GT, Herz A (1983) Ethanol and tetrahydroisoquinoline alkaloids do not produce narcotic discriminative stimulus effects. *Psychopharmacology* 81: 224-227
152. Shearman GT, Millan MJ, Herz A (1982) Lack of evidence for a role of endorphinergic mechanisms in mediating a discriminative stimulus produced by diazepam in rats. *Psychopharmacology* 78: 282-284
153. Shippenberg TS, Knappenberger D, Altshuler HL (1983) The biphasic effects of morphine and ethanol: discriminative stimulus properties. *Fed Proc* 42: 884
154. Shook JF, Kallman MJ, Dewey WL (1982) Discriminative stimulus properties of the R2 isomer of viminal: generalization to the morphine cue in rats. *Fed Proc* 41: 1302
155. Silverman PB, Ho BT (1982) A potent new antagonist of LSD discrimination. *Advances in Biochemical Psychopharmacology. Serotonin in Biochemical Psychiatry*. In: Ho BT, Schoolar JC, Usdin E (eds) Raven, New York 34: 321
156. Slifer BL, Balster RL (1983) Discriminative stimulus properties of stereoisomers of ethylketocyclazocine, ketocyclazocine and pentazocine in phencyclidine-trained squirrel monkeys. *Fed Proc* 42: 1363
157. Snoddy AM, Ganousis LG, Tessel RE (1982) Similar discriminative stimulus properties of amphetamine and nisoxetine in the mouse. *Fed Proc* 41: 1072
158. Snoddy AM, Tessel RE (1983) Nisoxetine and amphetamine share discriminative stimulus properties in mice. *Pharmac Biochem Behav* 19: 205-210
159. Solomon RE, Herling S, Domino EF, Woods JH (1982) Discriminative stimulus effects of N-substituted analogs of phencyclidine in rhesus monkeys. *Neuropharmacology* 21: 1329-1336
160. Solomon RE, Herling S, Woods JH (1982) Discriminative stimulus effects of monohydroxylated phencyclidine metabolites in rhesus monkeys. *Eur J Pharmac* 82: 233-237
161. Spencer DG, Lal H (1983) Discriminative stimulus properties of L-phenylisopropyl adenosine: blockade by caffeine and generalization to 2-chloroadenosine. *Life Sci* 32: 2329-2333
162. Stolerman IP, Pratt JA, Garcha HS (1982) Further analysis of the nicotine cue in rats. Drug discrimination: Applications in CNS pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 203-210
163. Stolerman IP, Pratt JA, Garcha HS, Giardini V, Kumar R (1983) Nicotine cue in rats analysed with drugs acting on cholinergic and 5-hydroxytryptamine mechanisms. *Neuropharmacology* 22: 1029-1037
164. Swedberg MDB, Jarbe TUC (1982) Morphine cue saliency: limits of discriminability and third state perception by pigeons. Drug discrimination: applications in CNS pharmacology. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 147-164
165. Tang AH, Code RA (1983) Discriminative stimulus properties of nalorphine in the rhesus monkeys. *J Pharmac Exp Ther* 227: 563-569
166. Valentino RJ, Herling S, Woods JH (1981) The relationship between the acute behavioral effects of narcotic antagonists and the narcotic-dependent state. *Psychopharmacology Bulletin* 17: 51-54
167. Valentino RJ, Herling S, Woods JH (1983) Discriminative stimulus effects of naltrexone in narcotic-naive and morphine-treated pigeons. *J Pharmac Exp Ther* 224: 307-313
168. Watanabe S (1983) D-Amphetamine discrimination established under a conditional discrimination procedure in pigeons. *Jpn J Psychopharmacol* 3: 45-50

169. Wessinger WD, Freeman AS, Martin BR, Brosius RA, Balster RL (1983) Discriminative stimulus effects of phencyclidine (PCP) and delta-9-tetrahydrocannabinol (THC) delivered in smoke to rats trained to discriminate IP injections of PCP from saline. *Fedn Proc* 42:1017
170. White FJ, Appel JB (1982) Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions. *Science* 216:535-537
171. White FJ, Appel JB (1982) The role of dopamine and serotonin in the discriminative stimulus effects of lisuride. *J Pharmacol Exp Ther* 221:421-427
172. White FJ, Appel JB (1982) Training dose as a factor in LSD-saline discrimination. *Psychopharmacology* 76:20-25
173. White FJ, Nielsen EB, Appel JB (1982) LSD-like effects of tetrahydro-beta-carbolines (THBC'S). *Advances in Biochemical psychopharmacology. Serotonin in Biochemical psychiatry*. In: Ho BT, Schooler JC, Usdin E (eds) Raven, New York 34:322-323
174. White JM, Holtzman SG (1982) Properties of pentazocine as a discriminative stimulus in the squirrel monkey. *J Pharmacol Exp Ther* 223:396-401
175. White JM, Holtzman SG (1983) Further characterization of the three-choice morphine cyclazocine and saline discrimination paradigm: opioids with agonist and antagonist properties. *J Pharmacol Exp Ther* 224:95-99
176. White JM, Holtzman SG (1983) Three-choice drug discrimination: phencyclidine-like stimulus effects of opioids. *Psychopharmacology* 80:1-9
177. Winger G, Bertalmio A, Woods JH (1982) Discriminative and reinforcing properties of the normetabolites of propoxyphene and meperidine. *Drug discrimination: applications in CNS pharmacology*. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 123-134
178. Winger G, Herling S (1982) Discriminative stimulus effects of pentobarbital in rhesus monkeys: tests of stimulus generalization and duration of action. *Psychopharmacology* 76:172-176
179. Witkin JM, Dykstra LA, Carter RB (1982) Acute tolerance to the discriminative stimulus properties of morphine. *Pharmacol Biochem Behav* 17:223-228
180. Woods JH, Herling S, Valentino RJ, Hein DW, Coale EH (1979) Narcotic drug discriminations by rhesus monkeys and pigeons. *Problems of Drug Dependence. NIDA research monograph* 27. US Government printing office, Washington DC, pp 128-134
181. Woods JH, Herling S, Young AM (1981) Comparison of discriminative and reinforcing stimulus characteristics of morphine-like opioids and two met-enkephalin analogues. *Neuropeptides* 1:409-419
182. Woods JH, Young AM, Herling S (1982) Classification of narcotics on the basis of their reinforcing, discriminative and antagonist effects in rhesus monkeys. *Fedn Proc* 41:221-227
183. Woolverton WL, Balster RL (1982) Behavioral pharmacology of local anaesthetics: reinforcing and discriminative stimulus effects. *Pharmacol Biochem Behav* 16:491-500
184. York JL, Bush R (1982) Studies on the discriminative stimulus properties of ethanol in squirrel monkeys. *Psychopharmacology* 77:212-216
185. Young AM, Woods JH, Herling S, Hein DW (1983) Comparison of the reinforcing and discriminative stimulus properties of opioids and opioid peptides. *The neurobiology of opiate reward mechanisms*. In: Smith JE, Lane JD (eds) Elsevier, Amsterdam, pp 147-174
186. Young R, Dewey WL (1982) Differentiation of the behavioral responses produced by barbiturates and benzodiazepines by the benzodiazepine antagonist Ro 15-1788. *Drug discrimination: Applications in CNS pharmacology*. In: Colpaert FC, Slangen JL (eds) Elsevier, Amsterdam, pp 235-240
187. Young R, Glennon RA, Dewey WL (1983) Discriminative stimulus effects of pentobarbital and diazepam. *Fed Proc* 42:1158
188. Young R, Glennon RA, Rosecrans JA (1980) Discriminative stimulus properties of the hallucinogenic agent DOM. *Commun Psychopharmacol* 4:501-506
189. Young R, Rosecrans JA, Glennon RA (1982) Comparative discriminative stimulus effects of 5-methoxy-N,N-dimethyltryptamine and LSD. *Life Sci* 30:2057-2062
190. Young R, Rosecrans JA, Glennon RA (1983) Behavioral effects of 5-methoxy-N,N-dimethyltryptamine and dose-dependent antagonism by BC-105. *Psychopharmacology* 80:156-160
191. Zenick H, Goldsmith M (1981) Drug discrimination learning in lead-exposed rats. *Science* 212:569-571

Received July 24, 1984; Final version December 5, 1984

Index

- | | | |
|--|---|--|
| Acceperone pretreatment 11 | 91, 122, 123, 125, 126, 129, 132, 157, 158, 168, 191 | Antipyrine 122 |
| Acetaldehyde cross-test 1, 90 | | Apomorphine 2, 3, 25, 83, 84, 133, 134 |
| Acetaminophen 122 | Amphetamine, (+)-cross-test 7, 19, 31, 37, 44, 47, 48, 52, 65, 88, 98, 102, 103, 105, 114, 115, 116, 127, 141, 149, 150, 157, 158, 159, 162, 166, 167, 171, 172, 174, 176, 180, 183 | Apomorphine cross-test 19, 29, 36, 47, 89, 102, 127, 149, 150, 162, 170, 171, 172, 174 |
| Acetone 122 | Amphetamine, (+)-pretreatment 8, 113 | Apomorphine pretreatment 19, 36 |
| Acetylsalicylic acid 122 | Amphetamine, (—)-cross-test 21, 89 | Arecoline 122 |
| Acetylsalicylic acid pretreatment 21 | Amphetamine, racemic cross-test 54 | Arecoline cross-test 19 |
| ACTH 122 | Amyl nitrate 122 | Artane, see trihexyphenidyl |
| ACTH analogues 135 | Amylobarbitone cross-test 37 | atropine 122 |
| Adenosine analogues 161 | Anabasin cross-test 127 | Atropine cross-test 21, 31, 127, 130, 159 |
| Adenosine analogues cross-test 161 | Analeptics 10, 38, 42, 43, 82, 110, 111, 120, 122, 123 | Atropine pretreatment 11, 21 |
| Adenosine analogues pretreatment 19, 22 | Analeptics cross-test 24, 44, 81, 93, 120, 166, 167, 180 | Baclofen cross-test 21 |
| Alpha-methyl-p-tyrosine 122 | Analeptics pretreatment 19, 76, 93, 113, 124 | Baclofen pretreatment 19 |
| Alpha-methyl-p-tyrosine pretreatment 124 | Anti-depressants 122, 131 | Barbitone 122 |
| Alprazolam pretreatment 19 | Anti-depressants cross-test 21, 65, 126, 131, 136, 141 | Barbitone cross-test 9, 123, 178, 181, 186, 187 |
| Althesin cross-test 19, 21 | Anti-depressants pretreatment 19, 21 | Barbiturates 4, 5, 9, 14, 66, 73, 79, 82, 92, 94, 95, 96, 101, 107, 122, 123, 124, 129, 132, 178, 186, 187 |
| Amantadine cross-test 19 | | Barbiturates cross-test 4, 5, 9, 19, 21, 31, 37, 48, 49, 66, 71, 73, 78, 79, 81, 82, |
| Amantadine pretreatment 19 | | |
| Amineptine cross-test 126 | | |
| Amitriptyline 122 | | |
| Amitriptyline cross-test 131, 136 | | |
| Amphetamine, (+)- 8, 25, 37, 52, 88, 89, | | |

- 98, 105, 107, 114, 117, 123, 124, 136, 143, 147, 157, 158, 174, 178, 180, 184, 186
- Barbiturates pretreatment 43, 179
- BC-105 cross-test 33, 45
- BC-105 pretreatment 2, 33, 45, 84, 171, 173, 188, 189, 190
- BC-2910 cross-test 138
- Bemegride 82, 122, 123
- Bemegride cross-test 81, 93, 166, 167, 180
- Bemegride pretreatment 76, 93, 124
- Benactyzine 122
- Benzodiazepines 4, 5, 9, 35, 38, 49, 66, 71, 72, 73, 74, 78, 79, 93, 95, 113, 120, 122, 123, 140, 142, 143, 152, 187
- Benzodiazepines cross-test 5, 19, 21, 31, 37, 38, 66, 73, 78, 79, 93, 101, 105, 107, 114, 120, 123, 127, 136, 141, 143, 147, 159, 178, 186, 187
- Benzodiazepines pretreatment 10, 19, 21, 22, 38, 42, 43, 44, 71, 79, 111, 120, 149, 173, 177
- Benztropine (Cogentin) 122
- Benztropine cross-test 19
- Beta-carbolines cross-test 61, 173
- Beta-CCM pretreatment 120
- Beta-phenylethylamine 65
- Bicuculline cross-test 120, 166, 167
- Bicuculline pretreatment 113, 120
- Birds 24, 49, 67, 68, 69, 75, 76, 81, 82, 89, 93, 96, 105, 112, 114, 115, 116, 117, 125, 164, 166, 167, 168, 179, 180, 185
- BOL (bromo-LSD) cross-test 33
- BOL (bromo-LSD) pretreatment 33
- Brain stimulation reward 39, 40, 41
- Bremazocine 147
- Bremazocine cross-test 148, 149, 150, 165
- BRL 13776 cross-test 21
- Bromazepam cross-test 78, 101, 143
- Bromocryptine cross-test 83
- Bromocryptine pretreatment 83
- Bufotenine cross-test 52
- Buprenorphine cross-test 112, 128, 138, 147
- Bupropion cross-test 126
- Buspirone 73
- Buspirone cross-test 73
- Butanol cross-test 9
- Butorphanol cross-test 76, 81, 138, 141, 174, 175
- Caffeine 122
- Caffeine beverages pretreatment 19
- Caffeine pretreatment 161
- Cannabidiol cross-test 21
- Cannabidiol pretreatment 21
- Cannabis, see delta-9/8-THC, hashish
- Carbachol 122
- Carboxysalsolinol, 3-, cross-test 26, 151
- Carboxysalsolinol, 3-, pretreatment 26
- Carisprodol 122
- Carisprodol, cross-test 123
- Cartazolat 187
- Cathinone 88
- Cathinone cross-test 48, 52, 53, 88
- Chloral hydrate cross-test 107, 123
- Chlordiazepoxide 9, 35, 95, 113, 122, 123
- Chlordiazepoxide cross-test 31, 37, 78, 101, 107, 114, 120, 123, 136, 143, 186, 187
- Chlordiazepoxide pretreatment 10
- Chlorimipramine cross-test 90
- Chlorimipramine pretreatment 21, 90
- Chlormethiazole 95
- Chloroform 122
- Chlorpromazine 122
- Chlorpromazine cross-test 71, 105, 107, 159, 165
- Chlorpromazine pretreatment 11, 19, 22, 149
- Chronic effects (e.g. tolerance) 8, 23, 42, 43, 70, 75, 111, 166, 167, 179
- Cimetidine cross-test 21
- Cimoxatone cross-test 126
- Cinanserin cross-test 33
- Cinanserin pretreatment 19, 21, 33, 155
- CL 218, 872 cross-test 113, 187
- Clobazam cross-test 178
- Clonazepam cross-test 78, 120, 143
- Clonazepam pretreatment 173
- Clonidine 11, 12, 37, 50
- Clonidine cross-test 13, 21, 37, 50, 141
- Clonidine pretreatment 21
- Clopipazan cross-test 20
- Clorazepate 38
- Clorazepate cross-test 78, 143
- Clorazepate pretreatment 38
- Clorgyline cross-test 126
- Clozapine 20, 122
- Clozapine pretreatment 19, 149
- Cocaine 29, 31, 36, 44, 48, 88, 91, 122, 123
- Cocaine analogues cross-test 183
- Cocaine cross-test 19, 47, 49, 65, 81, 88, 89, 126, 127, 162, 164
- Codeine 14, 122, 177, 181
- Codeine cross-test 76, 81, 85, 159, 178, 180, 181
- Cogentin, see benztropine
- Continuous reinforcement schedule 74, 77, 79, 85, 98, 99, 138, 141, 142, 143, 144, 145, 174, 175, 176
- CP-52,215 pretreatment 155
- Cyanamide pretreatment 90
- Cyclazocine 75, 85, 122, 123, 175, 176
- Cyclazocine cross-test 14, 16, 19, 21, 24, 67, 68, 77, 81, 85, 86, 98, 114, 138, 141, 148, 149, 150, 165, 166, 167, 174, 178, 180
- Cyclorphan cross-test 69, 75, 81
- Cyproheptadine 122
- Cyproheptadine cross-test 19, 20, 33, 78, 143
- Cyproheptadine pretreatment 7, 19, 33, 149, 171, 172
- Cytisine cross-test 47, 127, 162, 163
- D-al(2)-D-leu cross-test 146
- Delta-yohimbine, see raubasine
- Delta-9-tetrahydrocannabinol 21, 96
- Delta-9-tetrahydrocannabinol cross-test 19, 23, 89, 98
- Deprenyl cross-test 65, 126
- Desipramine cross-test 126, 131, 136
- Desipramine pretreatment 25
- DET cross-test 61
- Detrallophan cross-test 141
- Dexamethasone cross-test 21
- Dexoxadrol cross-test 18, 19, 22, 76, 81, 141
- Dextromethorphan 122
- Dextromethorphan cross-test 76, 80, 81, 86, 174, 178
- Dextrophan 76, 81
- Dextrophan cross-test 14, 67, 68, 80, 83, 86, 138, 141, 147, 149, 174, 175, 176, 178, 180
- Diazepam 28, 71, 72, 74, 78, 79, 93, 120, 122, 140, 142, 143, 152, 187
- Diazepam cross-test 9, 19, 21, 79, 93, 101, 105, 123, 141, 147, 159, 178, 186, 187
- Diazepam pretreatment 19, 21, 22, 42, 43, 44, 71, 111, 120, 149, 177
- Dichloroisoprenaline pretreatment 21
- Dimenhydrinate (Dramamine) 122
- Dimethoxyamphetamine, see DOET
- Dimethylphenobarbitone cross-test 107
- Diphenhydramine (benadryl) 122
- Diphenhydramine cross-test 145
- Diphenhydramine pretreatment 19, 145
- Diphenylhydantoin cross-test 71
- Diprenorphine cross-test 24, 166, 167
- Dipyridamole pretreatment 19
- Ditran 122
- Ditran cross-test 19
- Ditran pretreatment 19
- DMCN 120
- DMCN pretreatment 120
- DMT analogues cross-test 56, 59, 61
- DMT, see N,N-Dimethyltryptamine
- DOET cross-test 53, 54, 62
- DOM 51, 54, 57, 58, 60, 61, 62, 63, 64, 188
- DOM analogues cross-test 58, 60, 62, 63, 64
- DOM cross-test 53, 155
- Dopamine 122
- Dose versus dose training 27, 30, 90, 95, 103
- Doxapram pretreatment 19, 21
- Doxepin 122
- DPI cross-test 83
- DPI pretreatment 83
- Dramamine, see Dimenhydrinate
- Drug mixtures 45, 70, 157, 158, 164
- Drug versus drug training 6, 9, 50, 85, 95, 96, 103, 123, 129, 132, 170, 175, 176
- Emulphor EL-620 122
- Epinephrine, see adrenaline
- Ergometrine (ergonovine) cross-test 83, 84
- Ergometrine (ergonovine) pretreatment 83
- Etazolate cross-test 187
- Etazolate pretreatment 19
- Ethanol 1, 26, 39, 40, 41, 90, 93, 95, 119, 122, 123, 153, 184
- Ethanol cross-test 9, 93, 107, 123, 143, 151, 153
- Ethanol pretreatment 70
- Ether 122
- Ethoheptazine 122
- Ethoheptazine cross-test 81
- Ethosuximide 122
- Ethyl acetate 122
- Ethylcarbamate 122
- Ethylcarbamate (urethane) cross-test 123
- Ethylketazocine 75, 77, 100, 146, 147, 148, 180
- Ethylketazocine cross-test 14, 80, 81, 86, 128, 141, 146, 148, 149, 150, 156, 165, 167, 174, 175, 178, 180
- Ethylketazocine pretreatment 150
- Etorphine 180, 181, 185
- Etorphine cross-test 147
- Etoxadol cross-test 18
- External cues varied 35, 92, 94, 108, 129
- Fenfluramine crosstest 7, 127, 149
- Fentanyl 27, 30, 31, 102, 103, 112, 122, 123, 146, 148, 151
- Fentanyl cross-test 14, 148, 149, 150
- Fentanyl pretreatment 150
- FG 7142 120
- FG 7142 pretreatment 120
- Fixed interval schedule 108

- Fixed ratio schedule 2, 4, 5, 6, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 29, 30, 31, 32, 33, 36, 38, 39, 40, 41, 42, 43, 44, 48, 49, 50, 64, 65, 67, 68, 69, 71, 72, 73, 75, 76, 80, 81, 83, 84, 89, 93, 100, 104, 105, 110, 111, 113, 114, 116, 120, 126, 128, 131, 132, 133, 134, 135, 136, 139, 140, 146, 147, 148, 149, 150, 151, 153, 155, 156, 157, 158, 159, 160, 161, 164, 165, 166, 167, 169, 170, 172, 173, 177, 178, 180, 181, 183, 184, 185, 186, 191
- FK 33824 cross-test 180, 181
- Flaxedil, see gallamine
- Flunitrazepam cross-test 78, 143
- Fluoro-N,N-Diethyltryptamine, see FDET
- Fluoxetine cross-test 7
- Fluoxetine pretreatment 7
- Fluphenazine 122
- Flurazepam 122
- Flurazepam cross-test 101, 123, 143
- Flutroline pretreatment 155
- Food reinforcement 1, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 30, 31, 32, 33, 37, 38, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 56, 57, 58, 59, 60, 61, 62, 63, 65, 67, 68, 69, 70, 71, 72, 73, 75, 76, 80, 81, 89, 91, 93, 100, 102, 103, 105, 106, 108, 109, 110, 111, 113, 114, 115, 116, 118, 126, 127, 128, 130, 131, 132, 133, 134, 135, 136, 146, 147, 148, 149, 150, 151, 152, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 177, 178, 179, 180, 181, 183, 184, 185, 186, 188, 189, 190, 191
- Gallamine (Flaxedil) 122
- Gamma-hydroxybutyrate cross-test 21
- Gerbils 90, 95
- Glutethimide 122
- Glutethimide cross-test 71, 123
- Guanabenz cross-test 11, 12
- Hallucinogens 2, 3, 14, 16, 32, 33, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 69, 84, 104, 115, 117, 118, 122, 155, 156, 169, 170, 172, 173, 188, 189, 190
- Hallucinogens cross-test 2, 19, 21, 36, 51, 52, 53, 54, 56, 58, 59, 60, 61, 62, 78, 84, 89, 98, 101, 104, 141, 149, 150, 155, 165, 170, 174, 188, 189, 190
- Haloperidol 122
- Haloperidol cross-test 20, 21, 83, 141, 147
- Haloperidol pretreatment 2, 8, 11, 19, 21, 22, 33, 36, 83, 84, 89, 124, 134, 149, 150, 155, 171, 172, 173, 174, 189
- Harmaline cross-test 51, 61, 173
- Harmaline pretreatment 120
- Heroin 122
- Hexamethonium cross-test 130
- Hexamethonium pretreatment 46, 162, 163
- Histamine 122
- Humans 99, 119
- Hydralazine 13
- Hydralazine cross-test 11, 12
- Hydroxydopamine, 6-, pretreatment 25
- Hydroxytryptamine, 5-, 122
- Hydroxytryptophan 7, 45, 70
- Imipramine 122, 131
- Imipramine cross-test 21, 136, 141
- Imipramine pretreatment 19
- Indomethacin pretreatment 21
- Interlocking schedule 123
- Iproniazid 122
- Iproniazid cross-test 21
- Isoniazid pretreatment 71
- Isoprenaline (isoproterenol) 122
- Ketamine 14, 67, 68, 69, 80, 122, 123, 159, 160
- Ketamine cross-test 15, 19, 22, 114, 147, 149, 150, 165, 176, 178
- Ketocyclazocine (ketazocine) cross-test 19, 21, 78, 86, 98, 101, 141, 143, 156, 174, 175, 176, 180
- Lead pretreatment 191
- Lergotril cross-test 2, 84, 171
- Levallorphan 122
- Levallorphan cross-test 24, 86, 98, 138, 141, 175
- Levamisol pretreatment 19
- Levomethorphan cross-test 76, 81, 174
- Levorphanol 122
- Levorphanol cross-test 14, 67, 68, 76, 80, 81, 83, 86, 138, 141, 174, 175
- Levoxadrol cross-test 76, 81, 141
- Lidocaine (lignocaine) 122
- Lidocaine cross-test 183
- Lisuride 2, 3, 170, 171
- Lisuride cross-test 84, 170
- Lithium 122
- Lobeline 122
- Lofexidine cross-test 11, 12
- Loperamide cross-test 21
- Lorazepam 4, 5, 66
- Lorazepam cross-test 5, 66, 78, 143
- Loxapine cross-test 20
- Lysergic acid diethylamide 2, 3, 32, 33, 84, 118, 155, 170, 172, 173, 189
- Lysergic acid diethylamide cross-test 2, 19, 21, 54, 61, 84, 89, 98, 104, 141, 149, 150, 170, 189, 190
- M-hydroxybenzylhydrazine, see NSD-1015
- Malathion 122
- Mazes 35, 90, 91, 92, 94, 95, 122
- MIDA cross-test 53, 64, 98
- Mecamylamine 122
- Mecamylamine cross-test 19
- Mecamylamine pretreatment 19, 46, 124, 162, 163
- Medazepam cross-test 78, 143
- Meperidine, see pethidine
- Mephénytoin 122
- Meprobamate 122
- Meprobamate cross-test 9, 101, 123
- Mescaline 122
- Mescaline cross-test 33, 54, 104, 174
- Metazocine cross-test 69, 80, 138, 141
- Metergoline cross-test 7, 33, 163
- Metergoline pretreatment 7, 33, 46, 163
- Methacarbamol 122
- Methadone 122
- Methadone cross-test 76, 80, 81, 114, 125, 165
- Methaqualone 122
- Methaqualone cross-test 19, 71, 101
- Methiothepin pretreatment 7, 171, 172
- Methohexital 14
- Methohexital cross-test 178
- Methoxy-DMT, 5-, cross-test 171, 172
- Methoxycyclazocine cross-test 138
- Methoxytryptamine, 5-, cross-test 2, 172
- Methsuximide cross-test 107
- Methyldopa cross-test 11, 12
- Methylene dioxymphetamine, see MDA
- Methylphenidate 122
- Methylphenidate cross-test 44, 126
- Methylscopolamine 122
- Methyltryptamines cross-test 51, 52, 60, 61
- Methypylon 122
- Methypylon cross-test 123
- Methysergide 122, 124
- Methysergide cross-test 7, 33, 124
- Methysergide pretreatment 7, 11, 19, 33, 134, 155
- Metitepine cross-test 33
- Metitepine pretreatment 33
- Metrazol, see pentylentetrazol
- Metrapone 122
- Mezilamine cross-test 20
- Mezilamine pretreatment 19
- Mianserin cross-test 33
- Mianserin pretreatment 33, 45
- Mice 157, 158
- Midazolam cross-test 101, 127, 143
- Minoxidil cross-test 11, 12
- MK-212 cross-test 171, 172
- Monetary reinforcers 99
- Monkeys 4, 5, 14, 16, 17, 18, 48, 66, 80, 86, 100, 156, 159, 160, 165, 174, 177, 178, 180, 181, 182, 184, 185
- Morphine 50, 85, 106, 108, 109, 122, 124, 125, 128, 145, 153, 154, 164, 175, 179
- Morphine cross-test 19, 21, 24, 31, 37, 50, 67, 68, 69, 80, 81, 83, 89, 98, 102, 103, 107, 114, 124, 148, 149, 150, 151, 152, 153, 165, 166, 174, 176, 180, 181, 184
- Morphine pretreatment 19, 75, 166, 167, 179
- MR 1452 and MR 1453 cross-test 160, 167
- MR 2266 and MR 2267 cross-test 149, 150, 166, 167
- MR 2266 and MR 2267 pretreatment 148, 149, 150
- MRZ 2033 cross-test 147, 184
- Muscimol, cross-test 19, 21
- N-allylnormetazocine, see SKF 10, 047
- N,N-dimethyltryptamine cross-test 56
- N-propylnormetazocine cross-test 141
- Nalbuphine cross-test 138, 141, 174, 175
- Nalmexone cross-test 175
- Nalorphine 165
- Nalorphine cross-test 24, 80, 98, 102, 138, 141, 147, 149, 150, 167
- Naloxone 24, 122
- Naloxone cross-test 83, 141, 149, 150, 165, 166, 167, 180
- Naloxone pretreatment 1, 11, 17, 19, 21, 27, 31, 33, 36, 41, 77, 83, 106, 125, 128, 138, 139, 141, 145, 148, 149, 150, 152, 154, 165, 179
- Naltrexone 75, 122, 164, 166, 167, 180
- Naltrexone cross-test 24, 69, 81, 83, 86, 114
- Naltrexone methobromide cross-test 166, 180
- Naltrexone methobromide pretreatment 19
- Naltrexone pretreatment 1, 69, 74, 76, 81, 83, 85, 86, 114, 120, 124, 164, 174, 176, 177
- Nantradol cross-test 21
- Navane cross-test 19
- Negative reinforcement 35, 74, 77, 78, 79, 85, 86, 90, 91, 92, 94, 98, 101, 122, 138, 139, 140, 141, 142, 143, 144, 145, 174, 175, 176

- Neuroleptics 20, 122
 Neuroleptics cross-test 21, 71, 83, 105, 107, 141, 147, 159, 165
 Neuroleptics pretreatment 2, 8, 11, 19, 21, 22, 33, 36, 83, 84, 89, 124, 134, 149, 150, 155, 171, 172, 173, 174, 189
 Nialamide 122
 Nicotine 46, 47, 99, 103, 122, 123, 124, 127, 130, 162, 163
 Nicotine analogues cross-test 47, 127, 162, 163
 Nicotine cross-test 19, 31, 48, 102, 103, 124, 166, 167
 Nicotine pretreatment 120
 Nifedipine pretreatment 19
 Nikethamide 122
 Nimodipine pretreatment 19
 Nisoxetine 157, 158
 Nisoxetine cross-test 157, 158
 Nisoxetine pretreatment 157, 158
 Nitrazepam cross-test 78, 101, 143
 Nomifensine cross-test 126
 Noradrenaline (Norepinephrine) 122
 Norephedrine 122
 Normeperidine cross-test 177
 Normetazocine cross-test 86, 138
 Norpropoxyphene cross-test 177
 OME-DMT, 5-, (5-ome-dimethoxytryptamine) 52, 53, 56, 59, 189, 190
 OME-DMT, 5-, cross-test 51, 61, 188
 Opioids 6, 14, 24, 27, 28, 30, 31, 50, 75, 77, 81, 85, 87, 100, 102, 103, 106, 108, 109, 112, 122, 123, 124, 125, 128, 141, 145, 146, 147, 148, 149, 150, 151, 153, 154, 164, 165, 166, 167, 174, 175, 176, 177, 179, 180, 181, 182, 185
 Opioids cross-test 6, 14, 16, 17, 19, 21, 24, 31, 37, 50, 67, 68, 69, 75, 76, 77, 80, 81, 83, 85, 86, 89, 98, 100, 101, 102, 103, 107, 112, 114, 124, 125, 128, 138, 139, 141, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 156, 159, 165, 166, 167, 174, 175, 176, 177, 178, 180, 181, 182, 184
 Opioids pretreatment 1, 7, 11, 17, 19, 21, 27, 31, 33, 36, 41, 69, 74, 75, 76, 77, 81, 83, 85, 86, 106, 114, 120, 124, 125, 128, 138, 139, 141, 145, 148, 149, 150, 152, 154, 164, 165, 166, 167, 174, 176, 177, 179
 Oripavines cross-test 84, 100
 Oxazepam 49, 73, 122
 Oxazepam cross-test 73, 78, 143
 Oxilorphan cross-test 81, 138
 Oxolinic acid pretreatment 19
 Oxotremorine cross-test 21, 47, 127, 162
 Oxymorphone cross-test 169
 p-Hydroxyamphetamine cross-test 89
 Pargyline cross-test 21
 PCP (Phencyclidine) 6, 15, 16, 17, 18, 19, 22, 85, 86, 98, 114, 115, 116, 117, 122, 138, 139, 144, 156, 169, 176
 PCP analogues cross-test 18, 19, 22, 98, 144, 159, 160
 PCP cross-test 6, 21, 36, 67, 68, 78, 101, 141, 143, 147, 149, 150, 159, 160, 165, 174, 175
 Pempidine 122
 Pempidine pretreatment 124
 Pentazocine 122, 174
 Pentazocine cross-test 21, 24, 69, 80, 81, 83, 86, 98, 138, 141, 145, 147, 149, 150, 156, 180
 Pentazocine pretreatment 145
 Pentobarbitone 4, 5, 9, 66, 73, 79, 82, 92, 94, 95, 96, 101, 107, 122, 124, 129, 132, 178, 186, 187
 Pentobarbitone cross-test 4, 5, 19, 21, 31, 48, 49, 66, 71, 73, 78, 79, 81, 98, 105, 114, 117, 123, 124, 136, 143, 147, 157, 158, 180, 184, 186
 Pentobarbitone pretreatment 43, 179
 Pentylentetrazol (metrazol) 10, 38, 42, 43, 110, 111, 122
 Pentylentetrazol cross-test 44
 Pentylentetrazol pretreatment 19, 113
 Perlapine cross-test 20
 Pethidine (meperidine) 122
 Pethidine (meperidine) cross-test 138, 165, 177, 180
 Phencyclidine, see PCP
 Phenelzine 122
 Phenitron pretreatment 19, 21
 Phenobarbitone 122, 123
 Phenobarbitone cross-test 9, 21, 107, 178
 Phenoxylbenzamine 122
 Phenoxylbenzamine pretreatment 11, 12, 33, 37
 Phensuximide 122
 Phenolamine 122
 Phenolamine pretreatment 11
 Phenylethylmalondiamide cross-test 107
 Phenylisopropylamines 64
 Phenylisopropylamines cross-test 53, 57, 62, 63, 64
 Phenytoin 105, 122, 136
 Phenytoin cross-test 21, 107
 Phenytoin pretreatment 19
 Physostigmine 122
 Physostigmine cross-test 19, 98, 127, 130, 166, 167
 Physostigmine pretreatment 21, 124
 Picrotoxin 122
 Picrotoxin cross-test 24
 Pilocarpine 122
 Pilocarpine cross-test 21
 Pilocarpine pretreatment 21
 Piminondine 122
 Pimozide pretreatment 124
 Piperidine 122
 Piperoxane cross-test 166, 167
 Piperoxane pretreatment 37
 Piracetam 122
 Piracetam pretreatment 21
 Pirbuterol cross-test 19
 Pirenperone cross-test 33
 Pirenperone pretreatment 32, 33
 Piroxicam cross-test 21
 Piroxicam pretreatment 21
 Pizotifen or pizotyline, see BC-105
 Prazosin cross-test 11, 12, 13
 Prazosin pretreatment 19
 Primidone cross-test 107
 Procaine 122, 183
 Procaine cross-test 48
 Profadol 122
 Profadol cross-test 24, 81
 Propanolol 122
 Propanolol cross-test 11, 12, 71, 89, 141
 Propanolol pretreatment 11, 19, 21, 33, 89, 124
 Propoxyphene 122
- Propoxyphene cross-test 177
 Psilocin cross-test 52
 Psilocybin 104
 Psilocybin analogues cross-test 54, 104
 Psychomotor stimulants 3, 8, 29, 31, 36, 37, 44, 48, 52, 65, 88, 89, 91, 122, 123, 126, 129, 132, 157, 158, 168, 191
 Psychomotor stimulants cross-test 7, 19, 21, 25, 31, 37, 44, 47, 48, 49, 52, 54, 65, 81, 88, 89, 98, 102, 103, 105, 114, 115, 116, 125, 126, 127, 141, 149, 150, 157, 158, 159, 162, 164, 166, 167, 171, 172, 174, 176, 180, 183
 Psychomotor stimulants pretreatment 8, 19, 113
 Punishment schedule 91
 Pyrazoloquinolines cross-test 101, 140, 142, 143
 Pyrazoloquinolines pretreatment 101, 140, 142, 143
 Pyrillamine 122
 Pyrillamine pretreatment 33, 124
 QNB cross-test 19
 QNB pretreatment 19
 Quipazine 52, 70, 163
 Quipazine cross-test 33, 46, 52, 127, 134, 159, 162, 170, 171, 172
 Quipazine pretreatment 134
 Random interval schedule 168
 Rats 1, 2, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 19, 20, 21, 22, 23, 25, 26, 27, 29, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 70, 71, 72, 73, 77, 78, 79, 83, 84, 85, 88, 91, 92, 94, 98, 101, 102, 103, 104, 106, 107, 108, 109, 110, 111, 113, 118, 120, 123, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 161, 162, 163, 169, 170, 171, 172, 173, 175, 176, 183, 186, 188, 189, 190, 191
 Reserpine 122
 Reserpine pretreatment 124
 RMI 81582 cross-test 20
 Ro 11-6896 or 6893 cross-test 143
 Ro 15-1788 45
 Ro 15-1788 cross-test 38, 42, 43, 79, 111, 186
 Ro 15-1788 pretreatment 4, 5, 38, 43, 49, 66, 78, 79, 120, 186
 Ro 4-4602 7, 70
 Salbutamol cross-test 71
 Salsolinol cross-test 1, 151
 Scopolamine 124
 Scopolamine cross-test 19, 98, 114, 124, 149
 Scopolamine pretreatment 11, 19, 124
 Secobarbitone cross-test 174, 176
 Second-order schedules 114, 115, 116, 117
 SKF 10,047 (N-Allylnormetazocine) 6, 141, 145, 149, 150
 SKF 10,047 cross-test 14, 17, 19, 67, 68, 77, 81, 85, 86, 98, 138, 139, 148, 165, 174, 175, 176, 180
 SKF-525A pretreatment 148
 Spiperone pretreatment 33
 Strychnine 122
 Strychnine pretreatment 113
 Sulpiride cross-test 83
 Sulpiride pretreatment 19, 83
 Tacrine cross-test 19

- Tacrine pretreatment 21
- Tandem variable interval-fixed ratio schedule 37, 46, 47, 102, 103, 127, 162, 163, 179
- Temposil, see calcium carbamate
- Tetraethylammonium 122
- Tetrahydrocannabinols: see delta-8/9-THC
- Tetrahydropapaveroline cross-test 1, 151
- Tetramethylammonium 122
- THC metabolites and analogues cross-test 21
- THC metabolites and analogues pretreatment 21
- Thebaine cross-test 166
- Theophylline cross-test 19
- Theophylline pretreatment 19, 22
- Theoretical or review paper 2, 3, 28, 52, 54, 55, 85, 87, 96, 97, 106, 110, 121, 130, 137, 180, 182, 185
- Thioridazine 122
- Thioridazine cross-test 20
- THIP pretreatment 120
- Flujone cross-test 21
- Thyrotropin releasing hormone, see TRH
- Tifluadom cross-test 165
- Tiletamine cross-test 19, 22
- Time-course study 7, 11, 24, 47, 51, 53, 65, 72, 79, 81, 89, 90, 104, 112, 116, 127, 134, 144, 153, 160, 178, 181, 188
- Tolazoline 122
- Tolerance, see chronic effects
- Tracazolate cross-test 187
- Tracazolate pretreatment 19
- Training dose varied 8, 29, 30, 78, 85, 103, 141, 143, 157, 158, 164, 168, 170, 171, 172, 173, 180, 190
- Tranylepromine 122
- Tranylepromine cross-test 126
- TRH cross-test 166, 167, 180
- TRH pretreatment 19
- Triazolam cross-test 78, 101, 143
- Tribenzomine cross-test 20
- Trihexyphenidyl (artane) 122
- Trimethadione 122
- Trimethadione pretreatment 10
- Tripeleennamine cross-test 145
- Tripeleennamine pretreatment 145
- Tryptamine analogues cross-test 54, 61
- Tryptamine cross-test 52, 54
- U-50, 488e cross-test 165
- U-50, 488 cross-test 100
- UM-1046 cross-test 166, 167, 180
- Urethane, see ethylcarbamate
- Variable interval schedule 7, 8, 9, 26, 51, 53, 56, 57, 58, 59, 60, 61, 62, 63, 64, 70, 107, 109, 118, 130, 154, 188, 189, 190
- Vasopressin pretreatment 19
- Vehicles 122
- Veratridine cross-test 19
- Viminol cross-test 154
- Water reinforcement 2, 36, 83, 84, 104, 107, 120, 123, 170, 172, 173
- WIN 44,441 cross-test 167
- Xylamidine pretreatment 171, 172
- Yohimbine cross-test 21
- Yohimbine pretreatment 11, 12, 19, 21